Myocardial fibrosis is strongly associated with adverse outcome across a range of cardiovascular conditions [32,33] and further work is required to determine the association between myocardial fibrosis and outcome in patients receiving IL-2 therapy. This evidence concerns the gene IL2 and Myocardial fibrosis.